Loading...
XLON
RUA
Market cap18mUSD
Jul 09, Last price  
22.00GBP
1D
0.00%
1Q
46.67%
Jan 2017
10.60%
Name

Rua Life Sciences PLC

Chart & Performance

D1W1MN
XLON:RUA chart
P/E
—
P/S
3.06
EPS
—
Div Yield, %
—
Shrs. gr., 5y
28.52%
Rev. gr., 5y
23.89%
Revenues
4m
+8.42%
276,0001,484,0001,259,0001,362,0001,570,0003,146,7852,497,717251,379576,855625,564490,033404,000463,000489,0001,528,0001,625,0002,179,0002,191,0004,113,0004,459,355
Net income
-145k
L
-2,121,000-1,159,000-1,249,000-1,923,000-2,501,00035,6020-493,758-219,433-419,357-189,149-34,000-609,000-816,000-1,451,000-2,067,000-2,003,000-1,440,0001,000-145,334
CFO
-137k
L-37.44%
-816,000-1,139,000-1,389,000-2,050,000-1,527,00050,593346,192-23,998-189,81784,704-159,620347,000-429,000-431,000-1,423,000-2,361,000-1,174,000-1,328,000-219,000-137,000
Earnings
Jan 25, 2027

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

RUA Life Sciences plc, operating with its subsidiaries, delivers specialized polymers, various services, and finished products to the global medical device sector, spanning Europe, the United States, and other international markets. The company's operations encompass serving as a contract partner for the development and manufacturing of medical devices. Furthermore, it licenses its proprietary Elast-Eon and ECSil implantable co-polymers, which are integrated into cardiac and urological applications, including pacing leads, cardiac cannulae, and stent devices. RUA also grants licenses for its reaction injection molding technology, crucial for crafting high-precision medical device components. The firm is actively engaged in developing innovative bore polymer-sealed grafts, advanced soft tissue patches, and novel three-leaflet polymeric heart valves. Established in 1996 and based in Irvine, United Kingdom, the company adopted its current name, RUA Life Sciences plc, in June 2020, having previously been known as AorTech International plc.
URL
https://rualifesciences.com/
IPO date
Feb 12, 1997
Employees
48
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFY
2026‑032025‑092025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT